Human plasma kallikrein-kinin system: Physiological and biochemical parameters

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 7, Issue 3, 2009, Pages 234-250

  Bryant, J W ^a,b   Shariat Madar, Z ^b  

^a PFIZER INC   (United States)

^b UNIVERSITY OF MISSISSIPPI   (United States)

Author keywords

High molecular weight kininogen; Inflammation; Kallikrein inhibitors; Prekallikrein; Prolylcarboxypeptidase; Sepsis; The plasma kallikrein kinin system (KKS)

Indexed keywords

ACTIVATED PROTEIN C; ANTIBIOTIC AGENT; APROTININ; BLOOD CLOTTING FACTOR 12; BLOOD CLOTTING FACTOR 12A; BRADYKININ; BRADYKININ ANTAGONIST; BRADYKININ B2 RECEPTOR ANTAGONIST; CORTICOSTEROID; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROTRECOGIN; ECALLANTIDE; HIGH MOLECULAR WEIGHT KININOGEN; HYPERTENSIVE FACTOR; ICATIBANT; INOTROPIC AGENT; KALLIKREIN INHIBITOR; LEUKOCYTE MIGRATION INHIBITION FACTOR; NPC 17731; PKSI 527; PLASMA KALLIKREIN; PREKALLIKREIN; STEROID; UNCLASSIFIED DRUG;

ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC REACTION; ANGINA PECTORIS; ANGIOGENESIS; ANGIONEUROTIC EDEMA; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BIOLOGICAL ACTIVITY; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD FLOW; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DISSEMINATED INTRAVASCULAR CLOTTING; DOSE RESPONSE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG STRUCTURE; ENDOTOXEMIA; GENE EXPRESSION; HEART SURGERY; HEMODIALYSIS; HEMODYNAMICS; HUMAN; HYPERTENSION; INFLAMMATION; KALLIKREIN KININ SYSTEM; KIDNEY DISEASE; KIDNEY FAILURE; LOW DRUG DOSE; LUNG EMBOLISM; LUPUS ERYTHEMATOSUS; MOLECULAR DYNAMICS; NONHUMAN; PATHOGENESIS; PEMPHIGUS FOLIACEUS; PREGNANCY; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REGULATORY MECHANISM; REVIEW; SEPSIS; SICKLE CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; VASCULAR SURGERY; VASODILATATION;

AMINO ACID SEQUENCE; ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; HUMANS; KALLIKREIN-KININ SYSTEM; KALLIKREINS; MOLECULAR SEQUENCE DATA; PLASMA;

EID: 70349509809     PISSN: 18715257     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152509789105444     Document Type: Review

References (217)

1. Hooley. E.; McEwan, P.A.; Emsley, J. Molecular modelling of the Prekallikrein structure provide insights into HK binding and zymogen activation. J. Thromb. Haemost., 2007, 5(12), 2461.
2. Shariat-Madar, Z; Schmaier, A.H. Kininogen-cytokeratin 1 interactions in endothelial cell biology. Trends Cardiovasc. Med., 1999, 9(8), 238.
3. Tait, J.F.; Fujikawa, K. Primary structure requirements for the binding of human high molecular weight kininogen to plasma prekallikrein and factor XI. J. Biol. Chem., 1987, 262(24), 11651.
4. Thompson, R.E.; Mandle, R., Jr.; Kaplan, A.P. Association of factor XI and high molecular weight kininogen in human plasma. J. Clin. Invest., 1977, 60(6), 1376.
5. Colman, R.W.; Schmaier, A.H. The contact activation system: biochemistry and interactions of these surface-mediated defense reactions. Crit. Rev. Oncol. Hematol., 1986, 5(1), 57.
6. Griffin, J.H.; Cochrane, C.G. Recent advances in the understanding of contact activation reactions. Semin. Thromb. Hemost., 1979, 5(4), 254.
7. Saito, H. The "contact system" in health and disease. Adv. Intern. Med., 1980, 25, 217.
8. Schmaier, A.H.; McCrae, K.R. The plasma kallikrein-kinin system: its evolution from contact activation. J. Thromb. Haemost., 2007, 5(12), 2323.
9. Fong, D.; Chan, M.M.; Hsieh, W.T. Gene mapping of human cathepsins and cystatins. Biomed. Biochim. Acta, 1991, 50(4-6), 595.
10. Chung, D.W.; Fujikawa, K.; McMullen, B.A.; Davie, E.W. Human plasma prekallikrein, a zymogen to a serine protease that contains four tandem repeats. Biochemistry, 1986, 25(9), 2410.
11. Colman, R.W.; Schmaier, A.H. Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. Blood, 1997, 90(10), 3819.
12. Asakura, S.; Yang, W.; Sottile, J.; Zhang, Q.; Jin, Y.; Ohkubo, I.; Sasaki, M.; Matsuda, M.; Hirata, H.; Mosher, D.F. Opposing effects of low and high molecular weight kininogens on cell adhesion. J. Biochem., 1998, 124(3), 473.
13. Gustafson, E.J.; Schmaier, A.H.; Wachtfogel, Y.T.; Kaufman, N.; Kucich, U.; Colman, R.W. Human neutrophils contain and bind high molecular weight kininogen. J. Clin. Invest., 1989, 84(1), 28.
14. Jiang, Y.P.; Muller-Esterl, W.; Schmaier, A.H. Domain 3 of kininogens contains a cell-binding site and a site that modifies thrombin activation of platelets. J. Biol. Chem., 1992, 267(6), 3712.
15. Colman R.W. Interactions between the contact system, neutrophils and fibrinogen. Adv. Exp. Med. Biol., 1990, 281, 105.
16. Bano, B.; Kunapuli, S.P.; Bradford, H.N.; Colman, R.W. Structural requirements for cathepsin B and cathepsin H inhibition by kininogens. J. Protein Chem., 1996, 15(6), 519.
17. Nieziolek, M.; Kot, M.; Pyka, K.; Mak, P.; Kozik, A. Properties of chemically oxidized kininogens. Acta. Biochim. Pol., 2003, 50(3), 753.
18. Walsh, P.N. Platelet coagulation-protein interactions. Semin. Thromb. Hemost., 2004, 30(4), 461.
19. Vogel, R.; Kaufmann, J.; Chung, D.W.; Kellermann, J.; Muller-Esterl, W. Mapping of the prekallikrein-binding site of human Hkininogen by ligand screening of lambda gt11 expression libraries. Mimicking of the predicted binding site by anti-idiotypic antibodies. J. Biol. Chem., 1990, 265(21), 12494.
20. Weisel, J.W.; Nagaswami, C.; Woodhead, J.L.; La Cadena, R.A.; Page, J.D.; Colman, R.W. The shape of high molecular weight kininogen. Organization into structural domains, changes with activation, and interactions with prekallikrein, as determined by electron microscopy. J. Biol. Chem., 1994, 269(13), 10100.
21. Pixley, R.A.; Lin, Y.; Isordia-Salas, I.; Colman, R.W. Fine mapping of the sequences in domain 5 of high molecular weight kininogen (HK) interacting with heparin and zinc. J. Thromb. Haemost., 2003, 1(8), 1791.
22. Das, A.; Smalheiser, N.R.; Markaryan, A.; Kaplan, A. Evidence for binding of the ectodomain of amyloid precursor protein 695 and activated high molecular weight kininogen. Biochim. Biophys. Acta, 2002, 1571(3), 225.
23. Colman, R.W. Regulation of angiogenesis by the kallikrein-kinin system. Curr. Pharm. Des., 2006, 12(21), 2599.
24. Beaubien, G.; Rosinski-Chupin, I.; Mattei, M.G.; Mbikay, M.; Chretien, M.; Seidah, N.G. Gene structure and chromosomal localization of plasma kallikrein. Biochemistry, 1991, 30(6), 1628.
25. Ciechanowicz, A.; Bader, M.; Wagner, J.; Ganten, D. Extra-hepatic transcription of plasma prekallikrein gene in human and rat tissues. Biochem. Biophys. Res. Commun., 1993, 197(3), 1370.
26. Mandle, R.J.; Colman, R.W.; Kaplan, A.P. Identification of prekallikrein and high-molecular-weight kininogen as a complex in human plasma. Proc. Natl. Acad. Sci. USA, 1976, 73(11), 4179.
27. Tang, J.; Yu, C.L.; Williams, S.R.; Springman, E.; Jeffery, D.; Sprengeler, P.A.; Estevez, A.; Sampang, J.; Shrader, W.; Spencer, J.; Young, W.; McGrath, M.; Katz, B.A. Expression, crystallization, and three-dimensional structure of the catalytic domain of human plasma kallikrein. J. Biol. Chem., 2005, 280(49), 41077.
28. Adam, A.; Albert, A.; Calay, G.; Closset, J.; Damas, J.; Franchimont, P. Human kininogens of low and high molecular mass: quantification by radioimmunoassay and determination of reference values. Clin. Chem., 1985, 31(3), 423.
29. Schmaier, A.H. Plasma kallikrein/kinin system: a revised hypothesis for its activation and its physiologic contributions. Curr. Opin. Hematol., 2000, 7(5), 261.
30. Toossi, Z.; Sedor, J.R.; Mettler, M.A.; Everson, B.; Young, T.; Ratnoff, O.D. Induction of expression of monocyte interleukin 1 by Hageman factor (factor XII). Proc. Natl. Acad. Sci. USA, 1992, 89(24), 11969.
31. Ghebrehiwet, B.; Silverberg, M.; Kaplan, A.P. Activation of the classical pathway of complement by Hageman factor fragment. J. Exp. Med., 1981, 153(3), 665.
32. Qin, X.P.; Zeng, S.Y.; Tian, H.H.; Deng, S.X.; Ren, J.F.; Zheng, Y.B.; Li, D.; Li, Y. J.; Liao, D.F.; Chen, S.Y. Involvement of prolylcarboxypeptidase in the effect of rutaecarpine on the regression of mesenteric artery hypertrophy in renovascular hypertensive rats. Clin. Exp. Pharmacol. Physiol., 2009, 36(3), 319.
33. Phipps, J.A.; Clermont, A.C.; Sinha, S.; Chilcote, T.J.; Bursell, S.E.; Feener, E.P. Plasma Kallikrein Mediates Angiotensin II Type 1 Receptor-Stimulated Retinal Vascular Permeability. Hypertension, 2009, 53(2), 175.
34. Discipio, R.G. The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology, 1982, 45(3), 587.
35. Kaplan, A.P.; Kay, A.B.; Austen, K.F. A prealbumin activator of prekallikrein. 3. Appearance of chemotactic activity for human neutrophils by the conversion of human prekallikrein to kallikrein. J. Exp. Med., 1972, 135(1), 81.
36. Wachtfogel, Y.T.; Kucich, U.; James, H.L.; Scott, C.F.; Schapira, M.; Zimmerman, M.; Cohen, A.B.; Colman, R.W. Human plasma kallikrein releases neutrophil elastase during blood coagulation. J. Clin. Invest., 1983, 72(5), 1672.
37. Ichinose, A.; Fujikawa, K.; Suyama, T. The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J. Biol. Chem., 1986, 261(8), 3486.
38. Vascular wall lesion and disorder of endothelial vasoregulating function in patients with ankylosing spondylitis. Klin Med. (Mosk), 2007, 85(6), 54.
39. Colman, R.W.; Wong, P.Y. Participation of Hageman factor dependent pathways in human disease states. Thromb. Haemost. 1977, 38(4), 751.
40. Martinez-Brotons, F.; Oncins, J.R.; Mestres, J.; Amargos, V.; Reynaldo, C. Plasma kallikrein-kinin system in patients with uncomplicated sepsis and septic shock - comparison with cardiogenic shock. Thromb. Haemost., 1987, 58(2), 709.
41. Cerf, M.; Raidoo, D.; Fink, E.; Fritz, H.; Bhoola, K. Plasma kallikrein localisation in human blood vessels. Immunopharmacology, 1999, 44(1-2), 75.
42. Davie, E.W.; Ratnoff, O.D. Waterfall sequence for intrinsic blood clotting. Science, 1964, 18(145), 1310.
43. Furie, B.; Furie, B.C. The molecular basis of blood coagulation. Cell, 1988, 53(4), 505.
44. Hoffman, M.M.; Monroe, D.M. Rethinking the coagulation cascade. Curr. Hematol. Rep., 2005, 4(5), 391.
45. Gailani, D.; Renne, T. Intrinsic pathway of coagulation and arterial thrombosis. Arterioscler Thromb. Vasc. Biol., 2007, 27(12), 2507.
46. Yousef, G.M.; Diamandis, E.P. An overview of the kallikrein gene families in humans and other species: emerging candidate tumour markers. Clin. Biochem., 2003, 36(6), 443.
47. Colman, R.W.; Marder, V.J.; Clowes, A.W.; George, J.N.; Goldhaber, S.Z. In Hemostasis and Thrombosis: Basic Principles and Clinical Practice. 5th ed. Lippincott William and Wilkins: Philadelphia, 2006; pp. 271-283
48. Schapira, M.; Scott, C.F.; Colman, R.W. Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma. J. Clin. Invest., 1982, 69(2), 462.
49. Colman, R.W. Plasma and tissue kallikrein in arthritis and inflammatory bowel disease. Immunopharmacology, 1999, 43(2-3),103.
50. Coffman, L.G.; Parsonage, D.; D'Agostino, R., Jr.; Torti, F.M.; Torti, S.V. Regulatory effects of ferritin on angiogenesis. Proc. Natl. Acad. Sci. USA, 2009, 106(2), 570.
51. Colman, R.W. The contact system and angiogenesis: potential for therapeutic control of malignancy. Semin. Thromb. Hemost., 2004, 30(1), 45.
52. Colman, R.W. Regulation of angiogenesis by the kallikrein-kinin system. Curr. Pharm. Des., 2006, 12(21), 2599.
53. McCrae, K.R.; Donate, F.; Merkulov, S.; Sun, D.; Qi, X.; Shaw, D.E. Inhibition of angiogenesis by cleaved high molecular weight kininogen (HKa) and HKa domain 5. Curr. Cancer Drug Targets, 2005, 5(7), 519.
54. Xia, C.F.; Yin, H.; Yao, Y.Y.; Borlongan, C.V.; Chao, L.; Chao, J. Kallikrein protects against ischemic stroke by inhibiting apoptosis and inflammation and promoting angiogenesis and neurogenesis. Hum. Gene. Ther., 2006, 17(2), 206.
55. Zhang, J.C.; Qi, X.; Juarez, J.; Plunkett, M.; Donate, F.; Sakthivel, R.; Mazar, A. P.; McCrae, K.R. Inhibition of angiogenesis by two-chain high molecular weight kininogen (HKa) and kininogen-derived polypeptides. Can. J. Physiol. Pharmacol., 2002, 80(2), 85.
56. Cochrane, C.G.; Revak, S.D.; Wuepper, K.D. Activation of Hageman factor in solid and fluid phases: a critical role of kallikrein. J. Exp. Med., 1973, 138(6), 1564.
57. Cochrane, C.G.; Griffin, J.H. Molecular assembly in the contact phase of the Hageman factor system. Am. J. Med., 1979, 67(4), 657.
58. Etscheid, M.; Beer, N.; Fink, E.; Seitz, R.; Johannes, D. The hyaluronan-binding serine protease from human plasma cleaves HMW and LMW kininogen and releases bradykinin. Biol. Chem. 2002, 383(10), 1633.
59. Joseph, K.; Tholanikunnel, B.G.; Kaplan, A.P. Activation of the bradykinin-forming cascade on endothelial cells: a role for heat shock protein 90. Int. Immunopharmacol., 2002, 2(13-14), 1851.
60. Moreira, C.R.; Schmaier, A.H.; Mahdi, F.; da, M.G.; Nader, H.B.; Shariat-Madar, Z. Identification of prolylcarboxypeptidase as the cell matrix-associated prekallikrein activator. FEBS Lett., 2002, 523(1-3), 167.
61. Shariat-Madar, Z.; Mahdi, F.; Schmaier, A.H. Recombinant prolylcarboxypeptidase activates plasma prekallikrein. Blood, 2004, 103(12), 4554.
62. Shariat-Madar, Z.; Mahdi, F.; Schmaier, A.H. Assembly and activation of the plasma kallikrein/kinin system: a new interpretation. Int. Immunopharmacol., 2002, 2(13-14), 1841.
63. Wuepper, K.D.; Cochrane, C.G. Plasma prekallikrein: isolation, characterization, and mechanism of activation. J. Exp. Med., 1972, 135(1), 1.
64. Mandle, R., Jr.; Kaplan, A.P. Hageman factor substrates. Human plasma prekallikrein: mechanism of activation by Hageman factor and participation in hageman factor-dependent fibrinolysis. J. Biol. Chem., 1977, 252(17), 6097.
65. Rosing, J.; Tans, G.; Griffin, J.H. Surface-dependent activation of human factor XII (Hageman factor) by kallikrein and its light chain. Eur. J. Biochem., 1985, 151(3), 531.
66. Patston, P.A.; Gettins, P.; Beechem, J.; Schapira, M. Mechanism of serpin action: evidence that C1 inhibitor functions as a suicide substrate. Biochemistry, 1991, 30(36), 8876.
67. Guo, Y.L.; Colman, R.W. Two faces of high-molecular-weight kininogen (HK) in angiogenesis: bradykinin turns it on and cleaved HK (HKa) turns it off. J. Thromb. Haemost., 2005, 3(4), 670.
68. Blaukat, A. Structure and signalling pathways of kinin receptors. Andrologia, 2003, 35(1), 17.
69. Rhaleb, N.E.; Yang, X.P.; Nanba, M.; Shesely, E.G.; Carretero, O.A. Effect of chronic blockade of the kallikrein-kinin system on the development of hypertension in rats. Hypertension, 2001, 37(1), 121.
70. Kaplan, A.P.; Joseph, K, Shibayama, Y.; Nakazawa, Y.; Ghebrehiwet, B.; Reddigari, S.; Silverberg, M. Bradykinin formation. Plasma and tissue pathways and cellular interactions. Clin. Rev. Allergy Immunol., 1998, 16(4), 403.
71. Zhao, Y.; Qiu, Q.; Mahdi, F.; Shariat-Madar, Z.; Rojkjaer, R.; Schmaier, A.H. Assembly and activation of HK-PK complex on endothelial cells results in bradykinin liberation and NO formation. Am. J. Physiol. Heart Circ. Physiol., 2001, 280(4), H1821.
72. Joseph, K.; Kaplan, A.P. Formation of bradykinin: a major contributor to the innate inflammatory response. Adv. Immunol. 2005, 86, 159.
73. Sanden, C.; Enquist, J.; Bengtson, S.H.; Herwald, H.; Leeb-Lundberg, L.M. Kinin B2 receptor-mediated bradykinin internalization and metalloendopeptidase EP24.15-dependent intracellular bradykinin degradation. J. Pharmacol. Exp. Ther., 2008, 326(1), 24.
74. Sheikh, I.A.; Kaplan, A.P. Mechanism of digestion of bradykinin and lysylbradykinin (kallidin) in human serum. Role of carboxypeptidase, angiotensin-converting enzyme and determination of final degradation products. Biochem. Pharmacol., 1989, 38(6), 993.
75. Wennmalm, A. Endothelial nitric oxide and cardiovascular disease. J. Intern. Med., 1994, 235(4), 317.
76. Heffelfinger, S.C. The renin angiotensin system in the regulation of angiogenesis. Curr. Pharm. Des., 2007, 13(12), 1215.
77. Souza, D.G.; Lomez, E.S.; Pinho V, Pesquero, J.B.; Bader, M.; Pesquero, J.L.; Teixeira, M.M. Role of bradykinin B2 and B1 receptors in the local, remote, and systemic inflammatory responses that follow intestinal ischemia and reperfusion injury. J. Immunol., 2004, 172(4), 2542.
78. Shariat-Madar, Z.; Mahdi, F.; Warnock, M.; Homeister, J.W.; Srikanth, S.; Krijanovski, Y.; Murphey, L.J.; Jaffa, A.A.; Schmaier, A.H. Bradykinin B2 receptor knockout mice are protected from thrombosis by increased nitric oxide and prostacyclin. Blood, 2006, 108(1), 192.
79. Kimura, S.; Tsuji, H.; Nishimura, H.; Kato, H.; Ukimura, N.; Yano, S.; Kunieda, Y.; Kawano, H.; Nakagawa, K.; Nakagawa, M. Bradykinin enhances in vitro procoagulant and antifibrinolytic properties of rat vascular endothelial cells. Thromb. Res., 2002, 106(1), 41.
80. Witherow, F.N.; Dawson, P.; Ludlam, C.A.; Webb, D.J.; Fox, K.A.; Newby, D.E. Bradykinin receptor antagonism and endothelial tissue plasminogen activator release in humans. Arterioscler. Thromb. Vasc. Biol., 2003, 23(9), 1667.
81. Brown, N.J.; Gainer, J.V.; Murphey, L.J.; Vaughan, D.E. Bradykinin stimulates tissue plasminogen activator release from human forearm vasculature through B(2) receptor-dependent, NO synthase-independent, and cyclooxygenase-independent pathway. Circulation, 2000, 102(18), 2190.
82. Stephens, R.W.; Pollanen, J.; Tapiovaara, H, Leung, K.C.; Sim, P.S.; Salonen, E.M.; Ronne, E.; Behrendt, N.; Dano, K.; Vaheri, A. Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J. Cell Biol., 1989, 108(5), 1987.
83. Behrendt, N.; List, K.; Andreasen, P.A.; Dano, K. The prourokinase plasminogen-activation system in the presence of serpin-type inhibitors and the urokinase receptor: rescue of activity through reciprocal pro-enzyme activation. Biochem. J., 2003, 371(Pt 2), 277.
84. Schmaier, A.H.; Silver, L.; Adams, A.L.; Fischer, G.C.; Munoz, P.C.; Vroman, L.; Colman, R.W. The effect of high molecular weight kininogen on surface-adsorbed fibrinogen. Thromb. Res., 1984, 33(1), 51.
85. Vroman, L. Effect of absorbed proteins on the wettability of hydrophilic and hydrophobic solids. Nature, 1962, 3(196), 476.
86. Weiss, A.S.; Gallin, J.I.; Kaplan, A.P. Fletcher factor deficiency. A diminished rate of Hageman factor activation caused by absence of prekallikrein with abnormalities of coagulation, fibrinolysis, chemotactic activity, and kinin generation. J. Clin. Invest., 1974, 53(2), 622.
87. Hathaway, W.E.; Belhasen, L.P.; Hathaway, H.S. Evidence for a new plasma thromboplastin factor. I. Case report, coagulation studies and physicochemical properties. Blood, 1965, 26(5), 521.
88. Katsuda, I.; Maruyama, F.; Ezaki, K.; Sawamura, T.; Ichihara, Y. A new type of plasma prekallikrein deficiency associated with homozygosity for Gly104Arg and Asn124Ser in apple domain 2 of the heavy-chain region. Eur. J. Haematol., 2007, 79(1), 59.
89. Francois, D.; Trigui, N.; Leterreux, G.; Flaujac, C.; Horellou, M.H.; Mazaux, L.; Vignon, D.; Conard, J.; de, M.P. Severe prekallikrein deficiencies due to homozygous C529Y mutations. Blood Coagul. Fibrinolysis, 2007, 18(3), 283.
90. Currimbhoy, Z.; Vinciguerra, V.; Palakavongs, P.; Kuslansky, P.; Degnan, T.J. Fletcher factor deficiency and myocardial infarction. Am. J. Clin. Pathol., 1976, 65(6), 970.
91. LaDuca, F.M.; Tourbaf, K.D. Fletcher factor deficiency, source of variations of the activated partial thromboplastin time test. Am. J. Clin. Pathol., 1981, 75(4), 626.
92. Schmaier, A.H. The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. J. Clin. Invest., 2002, 109(8), 1007.
93. Pixley, R.A.; La Cadena, R.A.; Page, J.D.; Kaufman, N.; Wyshock, E.G.; Colman, R.W.; Chang, A.; Taylor, F.B., Jr. Activation of the contact system in lethal hypotensive bacteremia in a baboon model. Am. J. Pathol., 1992, 140(4), 897.
94. Annane, D. Resurrection of steroids for sepsis resuscitation. Minerva Anestesiol., 2002, 68(4), 127.
95. Colman, R.W.; Edelman, R.; Scott, C.F.; Gilman, R.H. Plasma kallikrein activation and inhibition during typhoid fever. J. Clin. Invest., 1978, 61(2), 287.
96. De La Cadena, R.A.; Laskin, K.J.; Pixley, R.A.; Sartor, R.B.; Schwab, J.H.; Back, N.; Bedi, G.S.; Fisher, R.S.; Colman, R.W. Role of kallikrein-kinin system in pathogenesis of bacterial cell wall-induced inflammation. Am. J. Physiol., 1991, 260(2 Pt 1), G213.
97. Bone, R.C.; Balk, R.A.; Cerra, F.B.; Dellinger, R.P.; Fein, A.M.; Knaus, W.A.; Schein, R.M.; Sibbald, W.J. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest, 1992, 101(6), 1644.
98. Riedemann, N.C.; Guo, R.F.; Ward, P.A. Novel strategies for the treatment of sepsis. Nat. Med., 2003, 9(5), 517.
99. Robson, W.; Newell, J. Assessing, treating and managing patients with sepsis. Nurs. Stand., 2005, 19(50), 56.
100. Sakkinen, P.A.; Cushman, M.; Psaty, B.M.; Kuller, L.H.; Bajaj, S.P.; Sabharwal, A.K.; Boineau, R.; Macy, E.; Tracy, R.P. Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort. Thromb. Haemost., 1998, 80(1), 134.
101. Herzum, I.; Renz, H. Inflammatory markers in SIRS, sepsis and septic shock. Curr. Med. Chem., 2008, 15(6), 581.
102. Russell, J.A. Management of sepsis. N. Engl. J. Med., 2006, 355(16), 1699.
103. Aboab, J.; Nardi, O.; Lipiner, D.; Sharshar, T.; Annane, D. Emerging drugs for the treatment of sepsis. Expert Opin. Emerg. Drugs, 2006, 11(1), 7.
104. Baue, A.E. Sepsis, systemic inflammatory response syndrome, multiple organ dysfunction syndrome, and multiple organ failure: are trauma surgeons lumpers or splitters? J. Trauma, 2003, 55(5), 997.
105. Mattsson, E.; Herwald, H.; Cramer, H.; Persson, K.; Sjobring, U.; Bjorck, L. Staphylococcus aureus induces release of bradykinin in human plasma. Infect. Immun., 2001, 69(6), 3877.
106. Marceau, F. Kinin B1 receptors: a review. Immunopharmacology, 1995, 30(1), 1.
107. Dellinger, R.P.; Levy, M.M.; Carlet, J.M.; Bion, J.; Parker, M.M.; Jaeschke, R.; Reinhart, K.; Angus, D.C.; Brun-Buisson, C.; Beale, R.; Calandra, T.; Dhainaut, J.F.; Gerlach, H.; Harvey, M.; Marini, J.J.; Marshall, J.; Ranieri, M.; Ramsay, G.; Sevransky, J.; Thompson, B.T.; Townsend, S.; Vender, J.S.; Zimmerman, J.L.; Vincent, J.L. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Crit. Care Med., 2008, 36(1), 296.
108. Fein, A.M.; Bernard, G.R.; Criner, G.J.; Fletcher, E.C.; Good, J.T., Jr.; Knaus, W. A.; Levy, H.; Matuschak, G.M.; Shanies, H.M.; Taylor, R.W.; Rodell, T.C. Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-controlled trial. CP-0127 SIRS and Sepsis Study Group. JAMA, 1997, 277(6), 482.
109. Otterbein, L.; Lowe, V.C.; Kyle, D.J.; Noronha-Blob, L. Additive effects of a bradykinin antagonist, NPC 17761, and a leumedin, NPC 15669, on survival in animal models of sepsis. Agents Actions, 1993, 39 Spec No:C125.
110. Annane, D.; Bellissant, E.; Bollaert, P.E.; Briegel, J.; Keh, D.; Kupfer, Y. Corticosteroids for severe sepsis and septic shock: a systematic review and meta-analysis. Br. Med. J., 2004, 329(7464), 480.
111. Wang, C.; Qin, J. Progress in application of recombinant human activated protein C in treating sepsis. Zhongguo Wuzhenxue Zazhi, 2008, 8(6), 1282.
112. Okajima, K.; Harada, N. Regulation of inflammatory responses by sensory neurons: molecular mechanism(s) and possible therapeutic applications. Curr. Med. Chem., 2006, 13(19), 2241.
113. Hooper, W.C.; Phillips, D.J.; Renshaw, M.A.; Evatt, B.L.; Benson, J.M. The up-regulation of IL-6 and IL-8 in human endothelial cells by activated protein C. J. Immunol., 1998, 161(5), 2567.
114. Gentry, C.A.; Gross, K.B.; Sud, B.; Drevets, D.A. Adverse outcomes associated with the use of drotrecogin alfa (activated) in patients with severe sepsis and baseline bleeding precautions. Crit. Care Med., 2009, 37(1), 19.
115. Putterman, C. Aprotinin therapy in septic shock. Acta Chir. Scand., 1989, 155(6-7), 367.
116. Dietrich, W.; Spath, P.; Ebell, A.; Richter, J.A. Prevalence of anaphylactic reactions to aprotinin: analysis of two hundred forty-eight reexposures to aprotinin in heart operations. J. Thorac. Cardiovasc. Surg., 1997, 113(1), 194.
117. Carretero, O.A.; Scicli, A.G. Local hormonal factors (intracrine, autocrine, and paracrine) in hypertension. Hypertension, 1991, 18(3 Suppl.), I58.
118. Hulthen, U.L.; Dymling, J.F.; Hokfelt, B. Kinins in relation to kallikrein activity, kininogen, electrolytes, aldosterone and catecholamines in urine from normal individuals. Acta Physiol. Scand., 1980, 110(3), 307.
119. Sharma, J.N.; Uma, K.; Noor, A.R.; Rahman, A.R. Blood pressure regulation by the kallikrein-kinin system. Gen. Pharmacol., 1996, 27(1), 55.
120. Yoshida, H.; Taniguchi, S.; Ura, N. [Molecular biology in regulation of kidney functions: Kallikrein-kinin system (bradykinin)]. Nippon Rinsho, 2006, 64(Suppl. 2), 199.
121. Lagneux, C.; Bader, M.; Pesquero, J.B.; Demenge, P.; Ribuot, C. Detrimental implication of B1 receptors in myocardial ischemia: evidence from pharmacological blockade and gene knockout mice. Int. Immunopharmacol., 2002, 2(6), 815.
122. Imamura, T.; Dubin, A.; Moore, W.; Tanaka, R.; Travis, J. Induction of vascular permeability enhancement by human tryptase: dependence on activation of prekallikrein and direct release of bradykinin from kininogens. Lab. Invest., 1996, 74(5), 861.
123. Fedoseev, G.B.; Zhikharev, S.S.; Goncharova, V.A.; Kachanova, T.A.; Razumovskaia, T.L. The role of serotonin, histamine and the kallikrein-kinin system in the pathogenesis of asphyxic attacks in bronchial asthma. Ter. Arkh., 1992, 64(1), 47.
124. Maruo, K.; Akaike, T.; Matsumura, Y.; Kohmoto, S.; Inada, Y.; Ono, T.; Arao, T.; Maeda, H. Triggering of the vascular permeability reaction by activation of the Hageman factor-prekallikrein system by house dust mite proteinase. Biochim. Biophys. Acta, 1991, 1074(1), 62.
125. Kharitonov, S.A.; Sapienza, M.M.; Chung, K.F.; Barnes, P.J. Prostaglandins mediate bradykinin-induced reduction of exhaled nitric oxide in asthma. Eur. Respir. J., 1999, 14(5), 1023.
126. Roisman, G.L.; Danel, C.J.; Lacronique, J.G.; henc-Gelas, F.; Dusser, D.J. Decreased expression of angiotensin-converting enzyme in the airway epithelium of asthmatic subjects is associated with eosinophil inflammation. J. Allergy Clin. Immunol., 1999, 104(2 Pt 1), 402.
127. Ikemura, T.; Sasaki, Y.; Ohmori, K. Inhibitory effect of NPC-17731 on BK-induced and antigen-induced airway reactions in guinea-pigs. Clin. Exp. Allergy, 1998, 28(5), 635.
128. Hogan, M.B.; Harris, K.E.; Protter, A.A.; Patterson, R. A bradykinin antagonist inhibits both bradykinin- and the allergen-induced airway response in primates. Proc. Assoc. Am. Physicians, 1997, 109(3), 269.
129. Akbary, A.M.; Wirth, K.J.; Scholkens, B.A. Efficacy and tolerability of Icatibant (Hoe 140) in patients with moderately severe chronic bronchial asthma. Immunopharmacology, 1996, 33(1-3), 238.
130. Kaplan, A.P. Chronic urticaria. Possible causes, suggested treatment alternatives. Postgrad. Med., 1983, 74(3), 209.
131. Marceau, F.; Bachvarov, D.R. Kinin receptors. Clin. Rev. Allergy Immunol., 1998, 16(4), 385.
132. Rodi, D.; Couture, R.; Ongali, B.; Simonato, M. Targeting kinin receptors for the treatment of neurological diseases. Curr. Pharm. Des., 2005, 11(10), 1313.
133. Trifilieff, A.; Gies, JP. Bradykinin and asthma. Rev. Mal. Respir., 1991, 8(4), 339.
134. lalibera-Joviliano R.; Reis, M.L.; Donadi, E.A. Kinin system in lupus nephritis. Int. Immunopharmacol., 2001, 1(9-10), 1889.
135. Pamuk, G.E.; Turgut, B.; Vural, O.; Demir, M.; Soy, M.; Bozkurt, G.; Celik, H. Thrombosis in systemic lupus erythematosus: effect of inherited thrombophilic mutations. Clin. Rheumatol. 2003, 22(4-5), 336.
136. Lehmann, A. Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery. Expert Opin. Biol. Ther., 2008, 8(8), 1187.
137. Caballero, T.; Lopez-Serrano, C. Anaphylactic reaction and antibodies to DX-88 (kallikrein inhibitor) in a patient with hereditary angioedema. J. Allergy Clin. Immunol., 2006, 117(2), 476.
138. Young, W.B.; Rai, R.; Shrader, W.D.; Burgess-Henry, J.; Hu, H.; Elrod, K.C.; Sprengeler, P.A.; Katz, B.A.; Sukbuntherng, J.; Mordenti, J. Small molecule inhibitors of plasma kallikrein. Bioorg. Med. Chem. Lett., 2006, 16(7), 2034.
139. Katsuura, Y.; Okamoto, S.; Ohno, N.; Wanaka, K. Effects of a highly selective synthetic inhibitor of plasma kallikrein on disseminated intravascular coagulation in rats. Thromb. Res., 1996, 82(4), 361.
140. Schapira, M.; Gardaz, J.P.; Py, P.; Lew, P.D.; Perrin, L.H.; Suter, P.M. Prekallikrein activation in the adult respiratory distress syndrome. Bull. Eur. Physiopathol. Respir., 1985, 21(3), 237.
141. Carvalho, A.C.; DeMarinis, S.; Scott. C.F.; Silver, L.D.; Schmaier, A.H.; Colman, R.W. Activation of the contact system of plasma proteolysis in the adult respiratory distress syndrome. J. Lab. Clin. Med., 1988, 112(2), 270.
142. Fuhrer, G.; Heller, W.; Junginger, W.; Grober, O.; Roth, K. Components of the kallikrein-kinin-system in patients with ARDS. Prog. Clin. Biol. Res., 1989, 308, 737.
143. Strizhakov, A.N.; Bol'shakova, T.D.; Kuznetsov, V.A.; Starkova, T.G. The kallikrein-kinin system in pregnant women with gestosis before and during complex therapy. Akush Ginekol (Mosk), 1989, 5, 33.
144. Sugi, T.; Makino, T. Antiphospholipid antibodies and kininogens in pathologic pregnancies: a review. Am. J. Reprod. Immunol., 2002, 47(5), 283.
145. Mohamed, M.; Larmie, E.T.; Singh, H.J.; Othman, M.S. Tissue kallikrein and kininogen levels in fetoplacental tissues from normotensive pregnant women and women with pregnancy-induced hypertension. Eur. J. Obstet. Gynecol. Reprod. Biol., 2007, 134(1), 15.
146. Hoffmeister, H.M.; Jur, M.; Wendel, H.P.; Heller, W.; Seipel, L. Alterations of coagulation and fibrinolytic and kallikrein-kinin systems in the acute and postacute phases in patients with unstable angina pectoris. Circulation, 1995, 91(10), 2520.
147. Hoffmeister, H.M.; Beyer, M.E.; Engel, Z.; Heller W. Activation of leukocytes and of the kallikrein-kinin system in patients with unstable angina pectoris. Clin. Cardiol., 1994, 17(1), 27.
148. Vinnikova, M.G.; Makarevich, I. Various indicators of hemostasis, plasminogen-plasmin and kinin systems of the blood and their inhibitors in patients with stable angina pectoris and post-infarction cardiosclerosis after graded physical load. Kardiologiia, 1987, 27(7), 56.
149. Discipio, R.G. The activation of the alternative pathway C3 convertase by human plasma kallikrein. Immunology, 1982, 45(3), 587.
150. Wachtfogel, Y.T.; Kucich, U.; James, H.L.; Scott, C.F.; Schapira, M.; Zimmerman, M.; Cohen, A.B.; Colman, R.W. Human plasma kallikrein releases neutrophil elastase during blood coagulation. J. Clin. Invest., 1983, 72(5), 1672.
151. Bergmann, S.; Zheng, D.; Barredo, J.; Abboud, M.R.; Jaffa, A.A. Renal kallikrein: a risk marker for nephropathy in children with sickle cell disease. J. Pediatr. Hematol. Oncol., 2006, 28(3), 147.
152. Schwartz, G.J.; Lerner, N.B. The kallikrein-kinin system in sickle cell nephropathy: does it play a role? J. Pediatr. Hematol. Oncol., 2006, 28(3), 111.
153. Braun, C.; Kleemann, T.; Birck, R.; Hilgenfeldt, U.; Riester, U.; Tschope, C.; van der Woude, F.J.; Rohmeiss, P. Increased activity of the renal kallikrein-kinin system in autosomal dominant polycystic kidney disease in rats, but not in humans. Int. Immunopharmacol., 2002, 2(13-14), 1949.
154. Harris. R.C.; Martinez-Maldonado, M. Angiotensin II-mediated renal injury. Miner Electrolyte Metab., 1995, i(4-5), 328.
155. Mojcik, C.F.; Levy, J.H. Aprotinin and the systemic inflammatory response after cardiopulmonary bypass. Ann. Thorac. Surg., 2001, 71(2), 745.
156. Campbell, D.J.; Dixon, B.; Kladis, A.; Kemme, M.; Santamaria, J.D. Activation of the kallikrein-kinin system by cardiopulmonary bypass in humans. Am. J. Physiol. Regul. Integr. Comp. Physiol., 2001, 281(4), R1059.
157. Wendel, H.P.; Scholpp, J.; Schulze, H.J.; Heller, W.; Schwenzer, N. Evaluation of markers of deep vein thrombosis in patients undergoing surgery for maxillofacial malignancies. J. Craniomaxillofac. Surg., 1999, 27(4), 266.
158. Samama, C.M.; Langeron, O.; Rosencher, N.; Capdevila, X.; Rouche, P.; Pegoix, M.; Berniere, J.; Coriat, P. Aprotinin versus placebo in major orthopedic surgery: a randomized, double-blinded, dose-ranging study. Anesth. Analg., 2002, 95(2), 287-93, table of contents.
159. Shcherbakova, E.G.; Varakina, N.I.; Iarovaia, G.A.; Belorusov, O.S.; Dotsenko, V.L.; Vorob'eva, L.S. Status of the kallikrein-kinin system, proteinase inhibitors and nonspecific resistance factors in patients with chronic kidney failure on hemodialysis as well as in kidney transplant recipients. Vopr. Med. Khim., 1991, 37(5), 40.
160. Schulman, G.; Hakim, R.; Arias, R.; Silverberg, M.; Kaplan, A.P.; Arbeit, L. Bradykinin generation by dialysis membranes: possible role in anaphylactic reaction. J. Am. Soc. Nephrol., 1993, 3(9), 1563.
161. Krieter, D.H.; Steinke, J.; Kerkhoff M.; Fink, E.; Lemke, H.D.; Zingler, C.; Müller, G.A.; Schuff-Werner, P. Contact activation in low-density lipoprotein apheresis systems. Artif. Organs, 2005, 29(1), 47.
162. Amore, A.; Guarnieri, G.; Atti, M.; Schena, F.P.; Coppo, R. Use of alkaline rinsing solution to prevent hypersensitivity reactions during hemodialysis: data from a multicentre retrospective analysis. J. Nephrol., 1999, 12(6), 383.
163. Farmer, J.A.; Torre-Amione, G. The renin angiotensin system as a risk factor for coronary artery disease. Curr. Atheroscler. Rep., 2001, 3(2), 117.
164. Campbell, D.J. The renin-angiotensin and the kallikrein-kinin systems. Int. J. Biochem. Cell Biol., 2003, 35(6), 784.
165. De Mello, W. Effect of extracellular and intracellular angiotensins on heart cell function; on the cardiac renin-angiotensin system. Regul. Pept., 2003, 114(2-3), 87.
166. Baltatu, O.; Bader, M. Brain renin-angiotensin system. Lessons from functional genomics. Neuroendocrinology, 2003, 78(5), 253.
167. Buchner, N.; Vonend, O.; Rump, LC. Pathophysiology of hypertension: what's new? Herz., 2006, 31(4), 294.
168. Lottermoser, K.; Weisser, B.; Hertfelder, H.J.; Wostmann, B.; Vetter, H.; Dusing, R. Antihypertensive drug treatment and fibrinolytic function. Am. J. Hypertens., 1998, 11(3 Pt 1), 378.
169. Zelezna, B.; Rydzewski, B.; Lu, D.; Olson, J.A.; Shiverick, K.T.; Tang, W.; Sumners, C.; Raizada, M.K. Angiotensin-II induction of plasminogen activator inhibitor-1 gene expression in astroglial cells of normotensive and spontaneously hypertensive rat brain. Mol. Endocrinol., 1992, 6(12), 2009.
170. Skurk, T.; Lee, Y.M.; Hauner, H. Angiotensin II and its metabolites stimulate PAI-1 protein release from human adipocytes in primary culture. Hypertension, 2001, 37(5), 1336.
171. Raizada, M.K.; Lu, D.; Yang, H.; Yu, K. AT1-receptors and cellular actions of angiotensin II in neuronal cultures of stroke prone-spontaneously hypertensive rat brain. Adv. Exp. Med. Biol., 1996, 396, 71.
172. Grobe, J.L.; Mecca, A.P.; Lingis, M.; Shenoy, V.; Bolton, T.A.; Machado, J.M.; Speth, R.C.; Raizada, M.K.; Katovich, M.J. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). Am. J. Physiol. Heart Circ. Physiol., 2007, 292(2), H736.
173. Dechend, R.; Muller, D.N.; Wallukat, G.; Homuth, V.; Krause, M.; Dudenhausen, J.; Luft, F.C. AT1 receptor agonistic antibodies, hypertension, and preeclampsia. Semin. Nephrol., 2004, 24(6), 571.
174. Katsuya, T.; Ogihara, T. Genes in rennin-angiotensin system. Nippon Rinsho, 2004, 62(1), 111.
175. Nagai, N.; Oike, Y.; Izumi-Nagai, K.; Koto, T.; Satofuka, S.; Shinoda, H.; Noda, K.; Ozawa, Y.; Inoue, M.; Tsubota, K.; Ishida, S. Suppression of choroidal neovascularization by inhibiting angiotensin-converting enzyme: minimal role of bradykinin. Invest. Ophthalmol. Vis. Sci., 2007, 48(5), 2321.
176. Mizutani, H.; Ohyanagi, S.; Nouchi, N.; Inachi, S.; Shimizu, M. Tissue factor and thrombomodulin expression on keratinocytes as coagulation/ anti-coagulation cofactor and differentiation marker. Australas. J. Dermatol., 1996, 37(Suppl. 1), S48-9.
177. Rosatelli, T.B.; Roselino, A.M.; lalibera-Joviliano, R.; Reis, M.L.; Donadi, E.A. Increased activity of plasma and tissue kallikreins, plasma kininase II and salivary kallikrein in pemphigus foliaceus (fogo selvagem). Br. J. Dermatol., 2005, 152(4), 650.
178. Damas, J. The brown Norway rats and the kinin system. Peptides, 1996, 17(5), 859.
179. Isordia-Salas, I.; Pixley, R.A.; Li, F.; Sainz, I.; Balfour, S.R.; Adam, A.; Colman, R.W. Chronic intestinal inflammation and angiogenesis in genetically susceptible rats is modulated by kininogen deficiency. Int. Immunopharmacol., 2002, 2(13-14), 1895.
180. Kaschina, E.; Stoll, M.; Sommerfeld, M.; Steckelings, U.M.; Kreutz, R.; Unger, T. Genetic kininogen deficiency contributes to aortic aneurysm formation but not to atherosclerosis. Physiol. Genomics, 2004, 19(1), 41.
181. Koch, M.; Bonaventura, K.; Spillmann, F.; Dendorfer, A.; Schultheiss, H.P.; Tschope, C. Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat model. Biol. Chem., 2008, 389(6), 719.
182. Kouyoumdjian, M.; Damas, J. The fate of plasma kallikrein in normal and kininogen-deficient rats. Arch. Physiol. Biochem., 1998, 106(1), 25.
183. Oh-Ishi, S. Biological regulation by the kallikrein-kinin system: a study with a kininogen-deficient rat strain. Nippon Yakurigaku Zasshi, 1993, 101(4), 209.
184. Oh-Ishi, S.; Hayashi, I.; Yamaki, K.; Utsunomiya I. Kininogen deficiency in the rat. Agents Actions Suppl., 1992, 38(Pt 1), 277.
185. Oh-Ishi, S.; Hayashi, I.; Satoh, K.; Nakano, T. Prolonged activated partial thromboplastin time and deficiency of high molecular weight kininogen in brown Norway rat mutant (Katholiek strain). Thromb. Res., 1984, 33(4), 371.
186. Colman, R.W.; Bradford, H.N.; Warner, A.H. High molecular weight kininogen, the extracellular inhibitor of thiol proteases, is deficient in hamsters with muscular dystrophy. Thromb. Res., 1989, 54(2), 115.
187. Cheung, P.P.; Kunapuli, S.P.; Scott, C.F.; Wachtfogel, Y.T.; Colman, R.W. Genetic basis of total kininogen deficiency in Williams' trait. J. Biol. Chem., 1993, 268(31), 23361.
188. Krijanovski, Y.; Proulle, V.; Mahdi, F.; Dreyfus, M.; Muller-Esterl, W.; Schmaier, A.H. Characterization of molecular defects of Fitzgerald trait and another novel high-molecular-weight kininogen-deficient patient: insights into structural requirements for kininogen expression. Blood, 2003, 101(11), 4430.
189. Colman, R.W. Structure-function correlates of human high molecular weight kininogen. Braz. J. Med. Biol. Res., 1994, 27(8), 1839.
190. Exner, T.; Barber, S.; Naujalis, J. Fitzgerald factor deficiency in an Australian aborigine. Med. J. Aust., 1987, 146(10), 545.
191. Gallimore, M.J.; Harris, S.L.; Jones, D.W.; Winter, M. Plasma levels of factor XII, prekallikrein and high molecular weight kininogen in normal blood donors and patients having suffered venous thrombosis. Thromb. Res., 2004, 114(2), 91.
192. Matheson, R.T.; Miller, D.R.; Lacombe, M.J.; Han, Y.N.; Iwanaga, S.; Kato, H.; Wuepper, K.D. Flaujeac factor deficiency. Reconstitution with highly purified bovine high molecular weight-kininogen and delineation of a new permeability-enhancing peptide released by plasma kallikrein from bovine high molecular weight-kininogen. J. Clin. Invest., 1976, 58(6), 1395.
193. Hayashi, H.; Ishimaru, F.; Fujita, T.; Tsurumi, N.; Tsuda, T.; Kimura, I. DNA analysis for the kininogen gene of patients with kininogen deficiency in Japan. Rinsho Ketsueki, 1989, 30(10), 1694.
194. Hayashi, H.; Ishimaru, F.; Fujita, T.; Tsurumi, N.; Tsuda, T.; Kimura, I. Molecular genetic survey of five Japanese families with high-molecular-weight kininogen deficiency. Blood, 1990, 75(6), 1296.
195. Ishimaru, F.; Dansako, H.; Nakase, K.; Fujii, N.; Sezaki, N.; Nakayama, H.; Fujii, N.; Komiyama, Y.; Iijima, K.; Takenaka, K.; Teshima, T.; Shinagawa, K.; Ikeda, K.; Niiya, K.; Harada, M. Molecular characterization of total kininogen deficiency in Japanese patients. Int. J. Hematol., 1999, 69(2), 126.
196. Iijima, K.; Nakamura, K. Coagulation and fibrinolysis associated with contact phase in plasma with high molecular weight kininogen deficiency. Rinsho Ketsueki, 1989, 30(10), 1702.
197. Lefrere, J.J.; Horellou, M.H.; Gozin, D.; Conard, J.; Muller, J.Y.; Clark, M.; Soulier, J.P.; Samama, M. A new case of highmolecular-weight kininogen inherited deficiency. Am. J. Hematol., 1986, 22(4), 415.
198. Raja, S.N.; Campbell, J.N.; Meyer, R.A.; Colman, R.W. Role of kinins in pain and hyperalgesia: psychophysical studies in a patient with kininogen deficiency. Clin. Sci., 1992, 83(3), 337.
199. Hayashi, H.; Koya, H.; Kitajima, K.; Kimura, I. Coagulation factor deficiency apparently related to the Fitzgerald trait: the first cases in Japan. Acta Med. Okayama, 1978, 32(1), 81.
200. Asmis, L.M.; Sulzer, I.; Furlan, M.; Lammle, B. Prekallikrein deficiency: the characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII. Thromb. Res., 2002, 105(6), 463.
201. Saito, H.; Ratnoff, O.D. Interactions among Hageman factor (HG, Factor XII), plasma thromboplastin antecedent (PTA, Factor XI), plasma prekallikrein (PK, Fletcher factor) and high molecular weight kininogen (HMW-K, Fitzgerald factor) in blood coagulation. Adv. Exp. Med. Biol., 1979, 120B, 61.
202. Donaldson, V.H.; Kleniewski, J.; Saito, H.; Sayed, J.K. Prekallikrein deficiency in a kindred with kininogen deficiency and Fitzgerald trait clotting defect. Evidence that high molecular weight kininogen and prekallikrein exist as a complex in normal human plasma. J. Clin. Invest., 1977, 60(3), 571.
203. Lombardi, A.M.; Sartori, M.T.; Cabrio, L.; Fadin, M.; Zanon, E.; Girolami, A. Severe prekallikrein (Fletcher factor) deficiency due to a compound heterozygosis (383Trp stop codon and Cys529Tyr). Thromb. Haemost., 2003, 90(6), 1040.
204. Scicli, A.G.; Mindroiu, T.; Scicli, G.; Carretero, O.A. Blood kinins, their concentration in normal subjects and in patients with congenital deficiency in plasma prekallikrein and kininogen. J. Lab. Clin. Med., 1982, 100(1), 81.
205. Wuillemin, W.A.; Furlan, M.; von Felten, A.; Lammle, B. Functional characterization of a variant prekallikrein (PK Zurich). Thromb. Haemost., 1993, 70(3), 427.
206. Saito, H.; Goldsmith, G.H., Jr. Plasma thromboplastin antecedent (PTA, factor XI): a specific and sensitive radioimmunoassay. Blood, 1977, 50(3), 377.
207. Stern, D.M.; Nossel, H.L.; Owen, J. Acquired antibody to factor XI in a patient with congenital factor XI deficiency. J. Clin. Invest., 1982, 69(6), 1270.
208. Kravtsov, D.V.; Wu, W.; Meijers. J.C.; Sun, M.F.; Blinder, M.A.; Dang, T.P.; Wang, H.; Gailani, D. Dominant factor XI deficiency caused by mutations in the factor XI catalytic domain. Blood, 2004, 104(1), 128.
209. Poon, M.C.; Moore, M.R.; Castleberry, R.P.; Lurie, A.; Huang, S.T.; Lehmeyer, J. Severe Fletcher factor (plasma prekallikrein) deficiency with partial deficiency of Hageman factor (factor XII): report of a case with observation on in vivo and in vitro leukocyte chemotaxis. Am. J. Hematol., 1982, 12(3), 261.
210. Iwaki, T.; Castellino, F.J. Plasma levels of bradykinin are suppressed in factor XII-deficient mice. Thromb. Haemost. 2006, 95(6), 1003.
211. Lodi, S.; Isa, L.; Pollini, E.; Bravo, A.F.; Scalvini. A. Defective intrinsic fibrinolytic activity in a patient with severe factor XII-deficiency and myocardial infarction. Scand. J. Haematol., 1984, 33(1), 80.
212. Patrassi, G.M.; Martinelli, S.; Vianello, C.; Girolami, A. Kallikrein and prekallikrein levels in a large number of congenital clotting deficiencies and abnormalities. Folia. Haematol. Int. Mag. Klin. Morphol. Blutforsch., 1982, 109(4), 644.
213. Chhibber, G.; Cohen, A.; Lane, S.; Farber, A.; Meloni, F.J.; Schmaier, A.H. Immunoblotting of plasma in a pregnant patient with hereditary angioedema. J. Lab. Clin. Med., 1990, 115(1), 112.
214. Cugno, M.; Cicardi, M.; Bottasso, B.; Coppola, R.; Paonessa, R.; Mannucci, P. M.; Agostoni, A. Activation of the coagulation cascade in C1-inhibitor deficiencies. Blood, 1997, 89(9), 3213.
215. Lammle, B.; Zuraw, B.L.; Heeb, M.J.; Schwarz, H.P.; Berrettini, M.; Curd, J.G.; Griffin, J.H. Detection and quantitation of cleaved and uncleaved high molecular weight kininogen in plasma by ligand blotting with radiolabeled plasma prekallikrein or factor XI. Thromb. Haemost., 1988, 59(2), 151.
216. Cugno, M.; Hack, C.E.; de Boer, J.P.; Eerenberg, A.J.; Agostoni, A.; Cicardi, M. Generation of plasmin during acute attacks of hereditary angioedema. J. Lab. Clin. Med., 1993, 121(1), 38.
217. Davis A.E. The pathophysiology of hereditary angioedema. Clin. Immunol., 2005, 114(1), 3.